Article
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Annals of internal medicine - 15 Dec 2015
Kohli Anita, Kattakuzhy Sarah, Sidharthan Sreetha, Nelson Amy, McLaughlin Mary, Seamon Cassie, Wilson Eleanor, Meissner Eric G, Sims Zayani, Silk Rachel, Gross Chloe, Akoth Elizabeth, Tang Lydia, Price Angie, Jolley Tim A, Emmanuel Benjamin, Proschan Michael, Teferi Gebeyehu, Chavez Jose, Abbott Stephen, Osinusi Anuoluwapo, Mo Hongmei, Polis Michael A, Masur Henry, Kottilil Shyam
Abstract excerpt
BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some patients. If effective, shorter therapeutic courses could improve adherence and treatment costs. OBJECTIVE: To determine factors predictive of SVR to 4 weeks of DAA treatment in patients with stage F0 to F2 liver fibrosis. DESIGN:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.